印度制药公司在研发产出方面落后于全球竞争者, Indian pharmaceutical companies lag global competitors in R&D output, per a report by FAST India and IIFL Securities.

由FAST India和IIFL证券公司编写的一份报告显示,印度制药公司在研究与开发(研发)指标方面落后于全球竞争者。 A report by FAST India and IIFL Securities reveals that Indian pharmaceutical companies are falling behind global competitors in research and development (R&D) metrics. 全球公司生产专利量是全球企业的5.6倍,每10亿美元收入出版物数是全球企业的8.4倍。 Global firms produce 5.6 times more patents and 8.4 times more publications per billion USD in revenue. 尽管存在这些差距,但印度制药部门仍扮演着重要角色,2022年出口额达到235亿美元。 印度制药部门占国内生产总值的1.72%,占全球通用市场的20%。 Despite these gaps, India's pharma sector, contributing 1.72% to GDP and accounting for 20% of the global generic market, remains a significant player, with exports reaching USD 23.5 billion in 2022.